by Emil Syundyukov, 17th of December 2024 E-mail: [email protected] | Linkedin: https://www.linkedin.com/in/syundyukov/

2024 at Longenesis

I am happy to see that this year at Longenesis can be called a year of commercial and product development results. This post summarizes 2024 in a nutshell — recognizing the team, our partners, and clients for the value brought to healthcare through digital solutions.

In 2024 we have pivoted and validated our focused value proposition with Life Science and Healthcare Institutions, leading to a Product-Market-Fit (PMF) and positive commercial results. Our team has successfully secured commercial traction with Life Science companies and Healthcare Institutions in Europe and GCC. Having such commercial partnerships, helped us to increase the revenue in 2023 and 2024, leading the company to profitability and positive growth in the long run.

🔑  Key facts of 2024:

• 850 000+ patients: empowered with our solutions for digital engagement and support throughout the patient journey and research studies in more than 10 therapeutic areas.
• Revised strategy: Longenesis team revised its strategy, now focusing on delivering technological solutions aimed at accelerating therapies time-to-patients in Europe and the Gulf regions
• Profitability: Longenesis becomes profitable in 2024! Within the last three years, we delivered continuous growth and commercial expansion. Thank you, dear partners and clients, for supporting and utilizing our technology!
• Commercial traction with leading Life Science companies: this year we've focused on engaging in partnerships with Life Science companies, where our solutions support identifying patients in need, as well as the outcomes of therapies in different therapeutic areas.
• 35+ Healthcare Providers and Academic Institutions: Engage is used in healthcare institutions across multiple specialties, including maternal, pediatric, psychiatry, GI, CVD, oncology, neurology, rehabilitation, multi-profile care, etc.
• Academic Traction: every year, we publish our work in academic journals, and this year is no exception. We published multiple articles in Q1 and Q2 journals and presented the results at 10+ conferences worldwide.
• Product Growth: we continuously develop new functionality, aiming to create a more robust experience for patients and study participants, as well as provide solution to HCPs and researchers, so they can focus on the clinical and research part, not the IT 🙂
• Commitment to Data Privacy and Security: Longenesis gets re-certified for ISO27701 and ISO27001.

Team

None of these achievements would have been possible without our incredible team. My dream was to have a place where people could work hand-in-hand on technology advancements towards better healthcare. Super happy to share this journey with you!

My deepest gratitude to each and every one of you, team!

A big part of the team enjoys a sudden summer tropical shower in Riga